Shandong Weigao Group Medical Polymer Crescita futura
Future criteri di controllo 1/6
Shandong Weigao Group Medical Polymer prevede che gli utili e i ricavi cresceranno rispettivamente di 10.1% e 7.1% all'anno. Si prevede che l'EPS crescerà di 10% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 9.2% in 3 anni.
Informazioni chiave
10.1%
Tasso di crescita degli utili
10.0%
Tasso di crescita dell'EPS
| Medical Equipment crescita degli utili | 39.9% |
| Tasso di crescita dei ricavi | 7.1% |
| Rendimento futuro del capitale proprio | 9.2% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 21 Nov 2024 |
Aggiornamenti recenti sulla crescita futura
Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report
Sep 24
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target
Aug 30Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results
Mar 28Recent updates
Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?
Nov 26Be Wary Of Shandong Weigao Group Medical Polymer (HKG:1066) And Its Returns On Capital
Nov 04Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report
Sep 24Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target
Aug 30Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk
Jun 25Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return
Jun 23Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year
May 31We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope
May 22Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Apr 23Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results
Mar 28Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon
Jan 09Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 22Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?
Nov 10Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Oct 05Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing
Aug 01Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?
Jul 19Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Jun 22Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?
Jun 09The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Apr 27Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Mar 17A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Feb 27Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes
Jan 18Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Dec 12Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate
Nov 29Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today
Nov 14Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year
Oct 03The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Sep 21Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt
Sep 05Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price
Aug 23Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors
Aug 08There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital
Jun 22Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year
Jun 08An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued
May 16Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?
May 03Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher
Mar 17Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?
Jan 28Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?
Jan 13Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 17Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly
Dec 05An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued
Oct 18Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?
Oct 06Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 15,585 | 2,501 | 2,201 | 3,576 | 6 |
| 12/31/2025 | 14,731 | 2,319 | 1,962 | 3,013 | 7 |
| 12/31/2024 | 13,819 | 2,135 | 2,086 | 2,716 | 7 |
| 6/30/2024 | 12,967 | 1,912 | 2,018 | 2,704 | N/A |
| 3/31/2024 | 13,098 | 1,957 | 2,066 | 2,751 | N/A |
| 12/31/2023 | 13,229 | 2,002 | 2,113 | 2,799 | N/A |
| 9/30/2023 | 13,398 | 2,221 | 1,639 | 2,539 | N/A |
| 6/30/2023 | 13,566 | 2,440 | 1,166 | 2,280 | N/A |
| 3/31/2023 | 13,657 | 2,602 | 1,173 | 2,287 | N/A |
| 12/31/2022 | 13,747 | 2,764 | 1,181 | 2,295 | N/A |
| 9/30/2022 | 13,903 | 2,676 | 1,433 | 2,573 | N/A |
| 6/30/2022 | 14,058 | 2,589 | 1,685 | 2,852 | N/A |
| 3/31/2022 | 13,633 | 2,432 | 1,803 | 2,969 | N/A |
| 12/31/2021 | 13,209 | 2,276 | 1,920 | 3,087 | N/A |
| 9/30/2021 | 12,923 | 2,288 | 2,021 | 3,088 | N/A |
| 6/30/2021 | 12,636 | 2,300 | 2,121 | 3,089 | N/A |
| 3/31/2021 | 12,129 | 2,194 | 1,971 | 2,938 | N/A |
| 12/31/2020 | 11,622 | 2,087 | 1,821 | 2,788 | N/A |
| 9/30/2020 | 11,139 | 1,998 | 1,557 | 2,533 | N/A |
| 6/30/2020 | 10,656 | 1,909 | 1,292 | 2,277 | N/A |
| 3/31/2020 | 10,520 | 1,879 | 1,315 | 2,300 | N/A |
| 12/31/2019 | 10,384 | 1,850 | 1,337 | 2,322 | N/A |
| 9/30/2019 | 9,993 | 1,805 | 1,456 | 2,347 | N/A |
| 6/30/2019 | 9,602 | 1,760 | 1,575 | 2,371 | N/A |
| 3/31/2019 | 9,205 | 1,616 | 1,500 | 2,295 | N/A |
| 12/31/2018 | 8,809 | 1,473 | 1,424 | 2,219 | N/A |
| 6/30/2018 | 7,465 | 1,255 | 383 | 1,812 | N/A |
| 3/31/2018 | 6,879 | 1,255 | N/A | 1,539 | N/A |
| 12/31/2017 | 6,293 | 1,255 | N/A | 1,266 | N/A |
| 6/30/2017 | 5,402 | 1,297 | N/A | 1,233 | N/A |
| 3/31/2017 | 5,511 | 1,165 | N/A | 1,143 | N/A |
| 12/31/2016 | 5,620 | 1,033 | N/A | 1,053 | N/A |
| 9/30/2016 | 6,484 | 1,010 | N/A | 1,042 | N/A |
| 6/30/2016 | 6,237 | 914 | N/A | 1,030 | N/A |
| 3/31/2016 | 6,078 | 1,013 | N/A | 1,041 | N/A |
| 12/31/2015 | 5,919 | 1,113 | N/A | 1,053 | N/A |
| 9/30/2015 | 5,878 | 1,237 | N/A | N/A | N/A |
| 6/30/2015 | 5,610 | 1,196 | N/A | 622 | N/A |
| 3/31/2015 | 5,548 | 1,161 | N/A | N/A | N/A |
| 12/31/2014 | 5,278 | 1,085 | N/A | 711 | N/A |
| 9/30/2014 | 5,011 | 307 | N/A | N/A | N/A |
| 6/30/2014 | 4,996 | 431 | N/A | 794 | N/A |
| 3/31/2014 | 4,769 | 376 | N/A | N/A | N/A |
| 12/31/2013 | 4,613 | 388 | N/A | 720 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di 1066 ( 10.1% all'anno) è superiore al tasso di risparmio ( 2.3% ).
Guadagni vs Mercato: Si prevede che gli utili di 1066 ( 10.1% all'anno) cresceranno più lentamente rispetto al mercato Hong Kong ( 11.5% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di 1066 cresceranno, ma non in modo significativo.
Ricavi vs Mercato: Si prevede che il fatturato di 1066 ( 7.1% all'anno) crescerà più lentamente rispetto al mercato Hong Kong ( 7.8% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di 1066 ( 7.1% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di 1066 sarà basso tra 3 anni ( 9.2 %).